Chronic renal failure and the associated erythropoietinresponsive anemia afflicts over 2 million domestic cats in the United States, resulting in morbidity that can affect the owner-pet relationship. Although treatment of cats with recombinant human erythropoietin (Epo) protein can be effective, response to the drug often dissipates over time, probably due to the development of antibodies reactive with the human protein. As an alternate approach to the treatment of this disease, we have developed a recombinant
Introduction
Vectors based on recombinant adeno-associated virus (rAAV) technology have recently shown great promise as mediators of stable gene transfer in a variety of settings. Of particular interest is the potential for rAAV vectors to program the sustained in vivo synthesis of therapeutic proteins. For example, in earlier work, other investigators have shown that rAAV vectors containing either the mouse or human erythropoietin (Epo) gene can transduce mouse muscle and cause a non-physiologic increase in hematocrit. 1, 2 More recent studies in non-human primates extended and confirmed the findings in mice. 3, 4 One the major applications for recombinant human Epo protein is the treatment of anemia associated with chronic renal failure. However, human Epo has been readily adopted in other disease states (like anemia caused by cancer chemotherapy), and its use has even extended to veterinary medicine. Cats afflicted with chronic renal failure have been successfully treated with repeated injections of human Epo, but response to the drug often dissipates over time, probably due to the development of antibodies reactive with the human protein. 5, 6 To circumvent the problem of untoward immune responses against the human protein, we have developed an rAAV vector containing the feline Epo gene (rAAV/feEpo) for the express purpose of treating the anemia of chronic renal failure in cats. In addition, the use of an rAAV vector to transfer the gene in vivo should adeno-associated virus vector containing the feline erythropoietin gene (rAAV/feEpo). This vector, when administered intramuscularly to normal healthy cats, caused a doserelated increase in hematocrit over a 7-week period after injection. Thus, the rAAV/feEpo vector holds promise as a simple, safe and effective therapy for the anemia of chronic renal failure in domestic cats. Gene Therapy (2000) 7, 534-539.
obviate the need for frequent injections. In the work described herein, we show that in normal cats, the rAAV/feEpo vector mediates a significant and sustained increase in hematocrit, and thus offers significant promise as a treatment for Epo-responsive anemia in cats.
Results
Construction and characterization of the rAAV/feEpo vector Feline Epo coding sequences were obtained by PCR and used to create a tripartite rAAV production construct that contained: (1) the Epo sequences under the control of the human CMV-IE promoter flanked by AAV ITR sequences; (2) the AAV rep and cap genes; and (3) the neo R gene (Figure 1 ). We showed that the construct could transiently produce Epo protein by immunoprecipitation, and then confirmed that the plasmid could direct the production of biologically active rAAV (data not shown). In the final step, a producer cell line was established by selection in G418-containing medium (see Materials and methods).
We first tested the function of the rAAV/feEpo in cultured cells. rAAV/feEpo purified from two different producer cell lines was used to transduce C12 cells that were concurrently infected with Ad5. C12 cells (HeLa cells that contain integrated copies of the AAV rep and cap genes 7 ) were used because the presence of the rep gene allows the replication of rAAV DNA, and hence gives high-level transgene expression. Conditioned medium was collected, loaded on a gel and analyzed by Western blot. As shown in Figure 2 , rAAV/feEpo mediated the production of immunologically cross-reactive material that comigrated with recombinant human Epo. Injection of the rAAV/feEpo vector into scid mice We next carried out a pilot experiment in mice to confirm that rAAV/feEpo was able to program the production of biologically active Epo in vivo. To avoid an immune Gene Therapy response against feline Epo, the experiment was carried out in severe combined immunodeficient (scid) mice. These mice are incapable of either cellular or humoral immune responses. 8 We injected six scid mice with 7 × 10 9 DNAse-resistant particles (DRP) each of rAAVfeEpo, and then measured their hematocrits over time. The values were steady for the first week then increased over the next 4 weeks and appeared to have reached a plateau thereafter. Over the course of the 8-week experiment, the average hematocrit of the treated mice rose from 42.7% to 72.2%, while three mice injected with a control rAAV showed a slight decrease in hematocrit (Figure 3a) . Five out of six of the treated mice showed an increase of at least 30 points in hematocrit (Figure 3b) .
Injection of the rAAV/feEpo vector into cats
Because the in vitro and in vivo pilot experiments were successful, we moved forward with testing the vector in healthy SPF cats. Six cats were enrolled in a dose 12 particles, respectively. Hematocrits were subsequently measured over time ( Figure 4 ). In the 2 weeks before the treatment, baseline hematocrits of the six cats were quite variable, ranging from 22 to 36. However, over the course of the experiment, we observed a significant increase in the hematocrits of the high-dose cats. The mean hematocrit of these cats before injection was 31.2%, while the mean at 6-8 weeks after injection was 59.5% (P = 0.028, two tailed t-test). There were smaller increases in the medium-and low-dose cats, that were not statistically significant with the small number of animals used. Comparing the pre-injection and 6-8-week measurements, the low dose cats went from a mean hematocrit of 26.5% to 33.7% (P = 0.41), while the medium dose cats went from a mean hematocrit of 26.2% to 38.7% (P = 0.147). The temporal increase in hematocrit was similar to that seen in mice, starting at 2 weeks and gradually reaching a plateau by 7 weeks. The ultimate rise in hematocrit was clearly related to dose, with the highest levels observed in the cats that received 5 × 10 12 particles ( Figure 4 ). The experiment was terminated at 8 weeks because the cats in the highest dose group had passed the threshold hematocrit of 60% that had been arbitrarily set in the animal use protocol; all cats were killed and necropsied at that time.
Serum Epo levels
Levels of Epo protein in serum were determined by a commercial radioimmunoassay. As shown in Table 1 , all the naive cats had serum Epo levels that were undetectable by the assay (Ͻ4.5 mIU/ml). The rAAV/feEpotreated cats all had detectable Epo in serum, ranging from 9.9 to 6600 mIU/ml. The levels did not precisely correlate with the administered dose of virus. Cat M2, which received the intermediate dose of rAAV (5 × 10 11 genomes), had the highest serum Epo level. However, cats H1 and H2 (5 × 10 12 genomes) showed the next two highest levels of Epo. Cat L1, which had the lowest Epo level, also had the lowest hematocrit response over the course of the experiment. A lack of correlation between serum Epo levels and hematocrit has also been noted in human subjects. Histological examination of tissues A complete histopathological examination of tissues from the treated cats was performed. There were no significant changes in either the right or left semimembranosus muscles. However, a consistent, dose-related effect was noted in the bone marrow ( Figure 5 ) and spleens (not shown). The marrow in cats H1 and H2 (5 × 10 12 particles) was 100% cellular and characterized by intense erythroid, myeloid hyperplasia. There were numerous megakaryocytes and many foci of follicular lymphoid hyperplasia. Likewise, the spleens from the same cats were slightly enlarged and exhibited marked multifocal extramedullary hematopoiesis with numerous megakaryocytes. The periarteriolar lymphoid sheaths contained large active follicles. Cat M1 (5 × 10 11 particles) had similar erythroid and myeloid hyperplasia but the marrow was only about 50-60% cellular. The spleen contained only occasional foci of extramedullary hematopoiesis (EMH) and scattered neutrophils. The lymphoid follicles were active. Cat M2 (5 × 10 11 particles) had a bone marrow that was only 20% cellular and exhibited normal erythroid and myeloid proliferation with normal maturation. The spleen had hyperplastic lymphoid follicles and scattered aggregates of neutrophils but only minimal evidence of EMH. The marrow in cats L1 and L2 (5 × 10 10 particles) ranged from 20 to 50% cellular. The erythroid and myeloid proliferation were judged to be in the normal range with normal maturation, but occasional foci of intense hyperplasia were present. The spleens from these cats had active follicular lymphoid tissue, scattered neutrophils but minimal to no EMH. No dose-related changes were noted in the livers of the cats. All livers had mild periportal vacuolar degeneration and occasional small foci of EMH. These findings were all entirely consistent with dose-graded responses to Epo.
Biodistribution of the rAAV/feEpo vector genome Because of the possibility that vector might escape from the injection site and transduce distant tissues, we sought to determine the distribution of vector genomes in tissues recovered at necropsy. Because of the large size of the semitendenosus/semimembranosus muscles, we took multiple samples from them, and also sampled a variety of other tissues of interest. The results are summarized in Table 2 . As expected, we found vector genomes in the injected muscle in each cat, and the levels detected roughly correlated with dose. We also detected vector sequences in a number of other tissues, especially liver, spleen and draining lymph nodes. The virus was occasionally found at low levels in kidney and uninjected skeletal muscle, but was not observed in brain or ovaries.
Discussion
The domestic cat population in the United States is estimated to be in excess of 61 million, and 2 to 3 million of these cats suffer from chronic renal failure and anemia. 10, 11 Although the treatment of symptomatic anemia will not reverse the ultimate outcome of renal failure, most cats will respond to a therapeutic boost in hematocrit with increased activity, and thus they are able to return to pre-morbid levels of interaction and companionship. Therefore, the development of a simple and effective therapy for the anemia of chronic renal failure in domestic cats seems warranted.
We show here that it is possible to raise and sustain the hematocrits of healthy cats using a gene therapy approach with an rAAV vector containing the feline Epo gene. The construct we used in the present study allows for constitutive expression from the human CMV-IE promoter. We followed this approach rather than attempting to use a regulated promoter system. 4, 12, 13 Although our unregulated promoter will not allow adjustments in gene expression (and hence hematocrit) following administration of the vector, it might have several advantages over regulated systems. First, most regulated systems require the expression of a foreign regulator protein that could provoke an immune response. Second, our approach will not require the administration of the regulatory substance that could potentially have undesirable side-effects. Instead, we would propose to approach the regulation of hematocrit by controlling the dosage of the recombinant virus. Normal, healthy cats have a rather large range of normal hematocrit values, so we anticipate that precise control of the hematocrit will not be required for successful therapy. The therapeutic window in anemic cats will be large, and we expect that the lowest dose of vector used in this study will produce a clinical effect in symptomatic cats.
As part of this small study, we were able to study the biodistribution of rAAV genomes after a single intramuscular injection. Not unexpectedly, we found genomes beyond the site of injection. The most prominent extramuscular tissues involved were liver, spleen and draining lymph nodes. This finding is entirely consistent with (1) escape of the vector into the blood circulation; and (2) movement of vector from the muscle to immediately adjacent lymph nodes. Genomes were infrequently found in heart or kidneys, and never found in brain or ovaries. It is important to note that our assay was performed on tissues from a single time-point (8 weeks after inoculation), and thus one should not conclude that (1) other tissues were not transduced at earlier times after injection; and (2) that any of the positive tissues were 'permanently' transduced.
Our data suggest that further development of the rAAV/feEpo vector as a treatment for anemia in cats is justified. The next phase of evaluation will involve clinical trials in cats with chronic renal failure and anemia to determine long-term safety, efficacy, dose and ultimate duration of clinical benefit.
Materials and methods

DNA constructs and cell lines
The feline Epo cDNA was cloned by RT-PCR from normal cat kidney tissue. Total RNA was prepared from a frozen cat kidney (Pel-Freez Biologicals, Rogers, AR, USA) using Trizol reagent (Life Technologies, Gaithersburg, MD, USA) according to the manufacturer's instructions. First strand cDNA was prepared with oligo(dT) [12] [13] [14] [15] [16] [17] [18] primer and Superscript reverse transcriptase (Life Technologies) by the provided protocol. The Epo cDNA was amplified by two rounds of nested PCR using Taq polymerase and standard reaction conditions. The primers for the first round had the sequences: 5′GCGGCGGCCGCYAGG CGCGGAGATG3′ and 5′GCGGCGGCCGCTGGAGT GTCCATGGGAC3′, while the primers for the second round were 5′GCGACGCGTCCACCATGGGGTCGTG CGAATGTC3′ and 5′CGGAGCTCTCACCTGTCTCCT CTTCG3′. PCR products were cloned into pCR2.1 (Invitrogen, Carlsbad, CA, USA) and sequenced. Because the two clones that were initially sequenced showed base substitutions (presumably due to misincorporation by Taq polymerase), they were used to reconstruct a clone that exactly matched the published sequence (Genbank accession number L10606). 14 The feEpo coding sequences from the corrected clone were excised with HindIII and EcoRI, filled in with Klenow fragment of DNA polymerase I, and ligated into the vector pTP⌬Not, digested with NotI, and treated with the Klenow fragment. pTP⌬Not is a derivative of pAAV/CMV/␤Gal/repcap/neo 15 that allows the removal of the ␤-galactosidase transgene by digestion with NotI. As shown in Figure 1 , the resulting construct, pTP-feEpo, contains the feline Epo coding sequence under the control of the human cytomegalovirus immediate-early (CMV-IE) promoter, with an SV40 chimeric intron and polyadenylation signal. This expression cassette is placed between AAV inverted terminal repeats; also present in the plasmid are the AAV genes rep and cap and a neomycin resistance gene allowing for the selection of stable cell lines.
The pTP-feEpo plasmid was transfected into HeLa cells with DOTAP (Roche Molecular Biochemicals, Indianapolis, IN, USA) and cell lines were selected in 700 g/ml G418. 51 cell lines were screened for rAAV synthesis by induction and measurement of packaged virus in crude lysates. Titers of rAAV particles were determined as previously described using an ABI 7700 Taqman Sequence detection system (PE Applied Biosystems, Foster City, CA, USA). 16 The highest producing cell line (designated feEpo 2A5) was used for large scale production of virus.
rAAV/feEpo production The cell line was induced and virus was purified as previously described. 16 Briefly, cells were infected with Ad5 at a multiplicity of 20, incubated until maximum cytopathic effect, lysed with deoxycholate, treated with benzonase, and heat treated at 56°C for 45 min. rAAV was purified from the cell lysate by chromatography on a POROS HE1/M heparin column using the BioCAD Sprint system (PerSeptive Biosystems, Framingham, MA, USA).
In vitro detection of Epo production
The ability of rAAV/feEpo to transduce cells and program Epo synthesis was tested in the C12 cell line.
16 Ad5 (10 7 p.f.u.) and 0.25 ml of a crude lysate containing 1.8 × 10 9 rAAV particles were used to coinfect approximately 80% confluent C12 cells in a six-well plate. After 20 h, the medium was removed and replaced by 0.7 ml of serum-free medium. The cells were incubated a further 3 h, and the conditioned medium was collected. Samples were electrophoresed on a 12.5% acrylamide SDS gel, transferred to PVDF membrane, and detected with rabbit anti-(human Epo) antiserum (Genzyme, Cambridge, MA, USA) using the ECL Plus Detection Kit (Amersham Pharmacia Biotech, Piscataway, NJ, USA). This rabbit antiserum was known by the manufacturer to cross-react with Epo of other mammalian species.
Injection of rAAV-feEpo into mouse skeletal muscle Scid mice (C3H background; Harlan Sprague-Dawley, Indianapolis, IN, USA) were injected with 50 l of normal saline containing 7 × 10 9 particles of rAAV-feEpo in the left quadriceps muscle. Control mice were injected with a like quantity of a GFP-containing rAAV. Immediately before the injection, and at weekly intervals thereafter, mice were bled by nicking of the tail vein and hematocrits were determined by sedimentation in microcapillaries.
Injection of rAAV-feEpo into cat skeletal muscle Specific pathogen-free (SPF) cats were purchased from Liberty Research (Waverly, NY, USA). Six females were anesthetized with 15-25 mg/kg ketamine HCl intramuscularly (Fort Dodge, Overland Park, KS, USA). Each ani-mal was injected in the right semitendenosus/ semimebranosus muscle with varying doses of rAAV/feEpo contained in 0.6 ml of sterile normal saline. At intervals of 1 week thereafter, blood was collected from the jugular vein into EDTA containing tubes and hematocrits were measured by a Model S-Plus Counter (Coulter Electronics, Hialeah, FL, USA). After 8 weeks, the animals were killed and a complete necropsy was performed; tissue samples were snap frozen for subsequent DNA preparation.
PCR analysis of the tissue distribution of the rAAV/feEpo vector genome DNA was prepared from frozen tissue samples using the Qiaamp kit (QIAgen, Chatsworth, CA, USA) by the manufacturer's instructions. The DNA concentrations were measured by a microplate assay using PicoGreen dye (Molecular Probes, Eugene, OR, USA) and a Perkin Elmer HTS 7000 plate reader (Norwalk, CT, USA). PCR reactions used 50 ng of template DNA in a 20 l volume. The 5′ primer was located in a chimeric SV40 intron originally derived from the pTP⌬Not vector and had the sequence 5′GCTGCGGAATTGTACCCG3′, while the 3′ primer was located within the feline Epo gene, having the sequence 5′GCTGTCACAGATGAGGCGAG3′. After 35 cycles of amplification, the products were separated on a 2% agarose gel, transferred to Genescreen Plus membrane (NEN Life Science, Boston, MA, USA), and detected by hybridization with a 5′ end labeled oligonucleotide having the sequence 5′GGACGCGTCGCAA GCCGA ATTGGCC3′. A control experiment showed that the assay could detect 10 copies of plasmid spiked into a negative sample, or about one viral genome per 1000 cells. To control for template quality, we showed that all genomic DNA preparations gave a product when amplified with control primers derived from the feline c-myc gene.
Histopathology of cat tissues
Tissues were harvested at death and fixed by immersion in cold 4% paraformaldehyde. Bone marrow, spleen, liver and the right (injection site), as well as left semimembranosus muscles were routinely processed for histologic evaluation. Tissues were dehydrated, embedded in paraffin, cut at 3-5 m, and stained with hematoxylin and eosin before permanent mounting.
Measurement of serum Epo concentration
Serum samples were obtained from the experimental cats before death and from four naive cats for comparison. Erythropoietin levels were determined by a commercial erythropoietin radioimmunoassay (EPO-Trac; Diasorin, Stillwater, MN, USA) using the suggested protocol. This assay, although developed for the measurement of human Epo, has previously been used to measure feline Epo. 17 Since purified feline erythropoietin was unavailable, the values for concentration are expressed as feline equivalents based on a human standard curve. The high and low thresholds of the assay are 4.5 and 290 mIU/ml, respectively. Where necessary, samples were diluted to bring them within these limits.
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